Stock Analysis on Net

CVS Health Corp. (NYSE:CVS) 

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

CVS Health Corp., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income 1,623 71 1,768 1,124 2,047 2,265 1,914 2,142 2,300 (3,409) 2,961 2,313 1,296 1,587 2,791 2,224 975 1,219 2,986 2,012
Depreciation and amortization 1,147 1,161 1,151 1,138 1,134 1,127 1,104 1,001 1,049 1,056 1,087 1,055 1,115 1,134 1,137 1,126 1,139 1,114 1,102 1,086
Loss on assets held for sale 349 12 2,521
Store impairments 1,358
Goodwill impairment 431
Stock-based compensation 137 133 133 137 127 154 204 103 106 105 147 89 138 114 145 87 112 109 83 96
Restructuring charges, impairment of long-lived assets 840 152
(Gain) loss on sale of subsidiary (250) (225) 2 (271)
(Gain) loss on early extinguishment of debt (491) 89 363 674 766
Deferred income taxes and other noncash items (162) (571) (124) (217) 100 (599) (68) 155 507 (1,969) (94) (187) (173) (275) (204) (166) (473) 76 (66) (35)
Accounts receivable, net (315) (3,784) (210) 3,008 (2,340) (3,116) (53) (751) (962) 678 (720) (1,967) 801 (1,120) (291) (2,093) 2,054 (1,331) 482 (2,715)
Inventories (457) (1,582) 277 1,660 (72) (495) 972 828 (1,020) (884) 869 (400) (362) (420) 638 879 (1,018) (958) 462 541
Other assets 812 1,391 595 (2,836) 8 395 342 (1,255) (255) 14 27 (352) 29 113 78 (223) 575 349 559 (1,119)
Accounts payable and pharmacy claims and discounts payable 166 978 2,601 (1,410) 1,152 2,584 1,085 (1,203) 910 1,317 59 1,974 (1,075) 2,271 1,126 576 (726) 1,824 (257) 1,928
Health care costs payable and other insurance liabilities (121) 1,297 (672) 2,253 (4,285) 345 (48) 4,382 (3,440) 3,220 (11) 1,478 (179) 244 (190) 294 243 (59) (554) 139
Other liabilities (479) (679) (2,430) 46 (507) (445) 456 2,036 (909) 6,474 1,343 (440) 968 1,079 617 188 10 (964) 2,322 1,372
Change in operating assets and liabilities, net of effects from acquisitions (394) (2,379) 161 2,721 (6,044) (732) 2,754 4,037 (5,676) 10,819 1,567 293 182 2,167 1,978 (379) 1,138 (1,139) 3,014 146
Adjustments required to reconcile net income to net cash provided by operating activities 237 (816) 1,321 3,779 (4,683) 451 3,994 5,296 (4,252) 12,532 2,482 1,250 2,709 3,934 3,056 668 2,592 655 4,133 1,293
Net cash provided by operating activities 1,860 (745) 3,089 4,903 (2,636) 2,716 5,908 7,438 (1,952) 9,123 5,443 3,563 4,005 5,521 5,847 2,892 3,567 1,874 7,119 3,305
Proceeds from sales and maturities of investments 2,719 3,216 2,265 2,153 2,182 1,907 1,749 1,891 1,194 1,175 1,790 2,570 1,687 1,612 1,770 2,177 2,677 1,080 1,422 1,288
Purchases of investments (2,514) (5,896) (3,236) (3,545) (2,418) (2,126) (2,141) (2,358) (1,307) (1,429) (1,536) (3,474) (2,546) (1,847) (2,439) (3,131) (3,262) (2,689) (2,153) (1,535)
Purchases of property and equipment (768) (670) (638) (705) (911) (545) (591) (984) (688) (580) (408) (1,051) (597) (608) (486) (829) (713) (534) (448) (742)
Proceeds from sale-leaseback transactions 101
Acquisitions, net of cash and restricted cash acquired (10) (12) (48) (25) (120) (18) (9,380) (7,094) (8) (6) (118) (7) (11) (27) (24) (84) (38) (60) (155) (613)
Proceeds from sale of subsidiaries, net of cash and restricted cash sold 679 15 (1,943) 6 834
Other 26 15 32 28 25 11 1 31 11 20 85 (31) 27 23 72 (5) (1) 1 5
Net cash used in investing activities (547) (3,347) (1,625) (2,094) (1,242) (771) (10,362) (8,514) (119) (805) (2,130) (1,993) (1,440) (847) (1,107) (1,867) (1,234) (1,370) (1,333) (1,597)
Commercial paper borrowings (repayments), net 1,319 800 (2,719) 2,519 200 (1,000) 1,000
Proceeds from issuance of short-term loan 5,000
Repayment of short-term loan (5,000)
Net borrowings (repayments) of short-term debt (252) 252 (255) 255
Proceeds from issuance of long-term debt 2,954 4,959 4,947 5,951 987 2,039 3,973 3,946
Repayments of long-term debt (3,067) (1,669) (19) (18) (432) (947) (1,425) (362) (16) (2,666) (1,515) (14) (2,431) (2,400) (2,374) (3,049) (5,138) (9,477) (8) (1,008)
Derivative settlements (7)
Repurchase of common stock 1 3 (3,027) 1 3 2 (2,018) (1,500) (2,000)
Dividends paid (838) (837) (858) (840) (779) (779) (795) (779) (719) (726) (740) (722) (660) (659) (650) (656) (644) (665) (663) (652)
Proceeds from exercise of stock options 19 114 25 203 35 122 24 96 41 162 51 297 109 110 118 212 15 83 12 154
Payments for taxes related to net share settlement of equity awards (4) (5) (145) (31) (6) (7) (134) (34) (33) (8) (267) (62) (7) (2) (156) (3) (13) (7) (52) (16)
Other 48 8 3 (33) 9 (89) 7 (128) 40 20 10 (149) 158 (3) 6 (17) (12) (4)
Net cash provided by (used in) financing activities 431 (1,588) 1,249 (1,227) (972) (2,697) 3,626 2,726 (2,187) (3,218) (2,461) (2,650) (2,831) (1,967) (3,314) (3,244) (3,735) (6,117) (978) 2,675
Net increase (decrease) in cash, cash equivalents and restricted cash 1,744 (5,680) 2,713 1,582 (4,850) (752) (828) 1,650 (4,258) 5,100 852 (1,080) (266) 2,707 1,426 (2,219) (1,402) (5,613) 4,808 4,383

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. CVS Health Corp. net cash provided by operating activities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. CVS Health Corp. net cash used in investing activities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. CVS Health Corp. net cash provided by (used in) financing activities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.